Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950338 | 1.00 | BCHE (0.54) | BCHEMEN1KMT2ASLC7A5NR1H3 | |
| SCHEMBL4947620 | 1.00 | BCHE (0.54) | BCHEMEN1KMT2ASLC7A5NR1H3 | |
| SCHEMBL3978325 | 0.92 | BCHE (0.44) | BCHEMEN1KMT2ASLC7A5NR1H3 | |
| SCHEMBL3978329 | 0.92 | BCHE (0.44) | BCHEMEN1KMT2ASLC7A5NR1H3 | |
| SCHEMBL4951131 | 0.85 | BCHE (0.54) | BCHEMEN1KMT2ANR1H3KDM4E | |
| SCHEMBL4951146 | 0.85 | BCHE (0.54) | BCHEMEN1KMT2ANR1H3KDM4E | |
| SCHEMBL3979279 | 0.83 | NR1H3 (0.52) | BCHEKMT2ANR1H3NR1H2KDM4E | |
| SCHEMBL3979283 | 0.83 | NR1H3 (0.52) | BCHEKMT2ANR1H3NR1H2KDM4E | |
| SCHEMBL4952918 | 0.80 | BCHE (0.50) | BCHEMEN1KMT2ASLC7A5NR1H3 | |
| SCHEMBL4952931 | 0.80 | BCHE (0.50) | BCHEMEN1KMT2ASLC7A5NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | BCHE 2160/4885MEN1 4182/4885KMT2A 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.